NCT00222872View on ClinicalTrials.gov

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
OsteoporosisOsteoporosis, Postmenopausal
Interventions
DRUG

Parathyroid Hormone-related Protein

PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.

DRUG

Placebo

Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Department of Health and Human Services

FED

lead

University of Pittsburgh

OTHER

NCT00222872 - 3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women | Biotech Hunter | Biotech Hunter